[EN] COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE COUMARINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER
申请人:LEAD DISCOVERY CENTER GMBH
公开号:WO2019057821A1
公开(公告)日:2019-03-28
The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
该发明提供了新型香豆素衍生物作为特异性线粒体RNA聚合酶抑制剂,用于治疗癌症。
Kinetic Resolution of Racemic 2-Hydroxyamides Using a Diphenylacetyl Component as an Acyl Source and a Chiral Acyl-Transfer Catalyst
2-hydroxyamide derivatives are produced based on the kineticresolution of racemic 2-hydroxyamides with a diphenylacetyl component and (R)-benzotetramisole ((R)-BTM), a chiral acyl-transfer catalyst, via asymmetric esterification and acylation. It was revealed that a tertiary amide can be used with this novel protocol to achieve high selectivity (22 examples; s-value reaching over 250). The resulting chiral
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
作者:Bernard Barlaam、Peter Ballard、Robert H. Bradbury、Richard Ducray、Hervé Germain、D. Mark Hickinson、Kevin Hudson、Jason G. Kettle、Teresa Klinowska、Françoise Magnien、Donald J. Ogilvie、Annie Olivier、Stuart E. Pearson、James S. Scott、Abid Suleman、Cath B. Trigwell、Michel Vautier、Robin D. Whittaker、Robin Wood
DOI:10.1016/j.bmcl.2007.11.052
日期:2008.1
initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration.
4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
申请人:Barlaam Bernard Christophe
公开号:US20100222344A1
公开(公告)日:2010-09-02
A quinazoline derivative of the Formula (I):
wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.